Innovating Cell Therapy
Our research and development efforts are focused on creating engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases therapeutic options and availability for patients. With our ACUA technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).
MEDIA & PRESS UPDATES
GET IN TOUCH
We’re a growing early-stage biotechnology company. We're looking for talented people who are passionate about innovating new medicines at the cutting-edge of science. See our job listings at:
6160 Bristol Parkway #300 Culver City, CA 90230